

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.**

wherein R<sub>1</sub> is a long chain fatty acid, R<sub>2</sub> is a long chain fatty chain-acid ~~between 11 and 25 carbons in length, and wherein the variable "n" is an integer between 11 and 46, and~~

wherein said compound is characterized by the ability to inhibit biological activity of phospholipase A<sub>2</sub>.

2) CANCEL

3) The compound of claim 1, wherein said compound is characterized by the ability to inhibit biological activity of cyclooxygenase-2

4) The compound of claim 1, wherein said R<sub>1</sub> long chain fatty acid is between 11 and 25 carbons in length.

5) The compound of claim 1, wherein said R<sub>2</sub> long chain fatty acid is between 11 and 25 carbons in length.

6) The compound of claim 1, wherein the variable "n" is an integer between 11 and 46.

7) The compound of claim 1, wherein R<sub>1</sub> represents a long chain fatty acid selected from the group consisting of:

- (a) CH<sub>3</sub>(CH<sub>2</sub>)<sub>10</sub>,
- (b) CH<sub>3</sub>(CH<sub>2</sub>)<sub>10</sub>(CH)<sub>2</sub>(CH<sub>2</sub>)<sub>7</sub>, and
- (c) CH<sub>3</sub>(CH<sub>2</sub>)<sub>12-1</sub>
- (d) CH<sub>3</sub>(CH<sub>2</sub>)<sub>14</sub>, and
- (e) CH<sub>3</sub>(CH<sub>2</sub>)<sub>16-5</sub>

8) The compound of claim 1, wherein R<sub>2</sub> represents a long chain fatty acid selected from the group consisting of:

- (a) CH<sub>3</sub>(CH<sub>2</sub>)<sub>10</sub>,
- (b) CH<sub>3</sub>(CH<sub>2</sub>)<sub>10</sub>(CH)<sub>2</sub>(CH<sub>2</sub>)<sub>7</sub>,

- (c)  $\text{CH}_3(\text{CH}_2)_{12}$ ,
- (d)  $\text{CH}_3(\text{CH}_2)_{14}$ , and
- (e)  $\text{CH}_3(\text{CH}_2)_{16}$ .

9) The compound of claim 1, wherein the variable “n” is an integer between 11 and 46, and wherein R1 and R2 each represent a long chain fatty acid selected from the group consisting of:

- (a)  $\text{CH}_3(\text{CH}_2)_{10}$ ,
- (b)  $\text{CH}_3(\text{CH}_2)_{10}(\text{CH})_2(\text{CH}_2)_7$ ,
- (c)  $\text{CH}_3(\text{CH}_2)_{12}$ ,
- (d)  $\text{CH}_3(\text{CH}_2)_{14}$ , and
- (e)  $\text{CH}_3(\text{CH}_2)_{16}$ .

10) CANCEL

11) CANCEL

12) CANCEL

13) CANCEL

14) CANCEL

15) CANCEL

16) CANCEL

17) CANCEL


18) CANCEL

19) CANCEL

20) CANCEL

21) CANCEL

22) A composition of matter comprising one or more lipids having the formula



wherein R<sub>1</sub> is a long chain fatty acid chain between 11 and 25 carbons in length, R<sub>2</sub> is a long chain fatty acid chain between 11 and 25 carbons in length, and wherein the variable "n" is an integer between 11 and 46, and

wherein said compound is further characterized by the ability to inhibit biological activity of phospholipase A<sub>2</sub> cyclooxygenase-2.

23) CANCEL

24) CANCEL

25) The composition of matter of claim 22~~1~~, wherein said composition is a pharmaceutical composition

26) The composition of matter of claim 25, further comprising a pharmaceutically acceptable carrier.

27) The composition of matter of claim 22~~1~~, wherein said composition is a foodstuff.

28) The composition of matter of claim 22~~1~~, wherein said composition is a dietary supplement.

29) The composition of matter of claim 22~~1~~, wherein said composition is a cosmetic.

30) The composition of matter of claim 26~~25~~, further comprising a delivery form selected from the group consisting of: a tablet, a capsule, a syrup, a dragee, a suspension, an elixer, a solution, a powder, granules, an emulsion, microspheres, nanospheres, lipid vesicles, polymeric vesicles, ~~or an injectable~~, an ointment, a cream, a milk, an impregnated pad, a gel, a spray, and a lotion.

31) CANCEL

32) CANCEL

33) CANCEL

34) CANCEL

35) CANCEL

36) CANCEL

37) CANCEL

38) CANCEL

39) CANCEL

40) A method for treating an inflammation related condition in a mammal comprising the step of administering a composition according to claim ~~28~~25.

41) A method for treating an inflammation related condition in a mammal comprising the step of administering a composition according to claim ~~29~~28.


42) CANCEL

43) CANCEL

44) CANCEL

45) CANCEL

46) A method for treating an inflammation related condition in a mammal comprising the step of administering an effective amount of a composition of matter comprising one or more lipids having the formula



Wherein  $\text{R}_1$  is a long chain fatty acid ~~between 11 and 25 carbons in length~~,  $\text{R}_2$  is a long chain fatty acid~~between 11 and 25 carbons in length~~, and wherein the variable “n” is an integer between 11 and 46.

47) The method of claim 46, wherein said composition of matter is a pharmaceutical composition ~~further comprising a pharmaceutically acceptable carrier.~~

- 48) The method of claim 46, wherein said composition of matter is a foodstuff.
- 49) The method of claim 46, wherein said composition of matter is a dietary supplement.
- 50) The method of claim 46, wherein said composition of matter is a cosmetic.
- 51) CANCEL
- 52) CANCEL
- 53) CANCEL
- 54) CANCEL
- 55) CANCEL
- 56) CANCEL
- 57) CANCEL
- 58) CANCEL
- 59) CANCEL
- 60) CANCEL